4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Background Data from a 5-year follow-up of outcomes after transcatheter edge-to-edge
repair of severe mitral regurgitation, as compared with outcomes after maximal doses of …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …